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INTRODUCTION 
 Considerable progress has been made in the diagnosis and management 
of Urolithiasis but advances in our understanding of stone formation have not 
paralleled this. We still wonder why in a family some form stones while others 
don’t, though they are living in the same environment and consuming the same 
diet. The precipitating factor and sequence of events that lead to the formation of 
a kidney stone remains elusive.  
 The likelihood of forming another stone after the first episode is about 10% 
at 1 year, 30-40% at 5 year, 50-60% at 10 years and possibly 95-100% at 20 to 
25 years.1-4  
 Supersaturation is the driving force behind crystal formation in the 
kidneys. Many physiologic and metabolic derangements have been implicated in 
the etiology of renal stone formation, but differentiating among these various 
causes was difficult until the late 1970s. In 1975 Pak et al.5 developed a simple 
test to identify the underlying cause of urolithiasis, which was processed into an 
ambulatory protocol in 1978.6 This protocol disclosed a physiologic abnormality in 
nearly 90% of cases and provided a definitive diagnosis in 95% of the patients.3,4 
This ambulatory instrument made diagnostic separation and classification of 
urolithiasis more accessible and more practical for all patients. The ability to 
distinguish among the underlying physiologic disturbances allowed the 
application of a selective treatment programme on the basis of correction of the 
specific physiologic derangement. Over the years, selective therapies were 
formed that contain three different components: high fluid intake, specific diet, 
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and medication. Although much is understood about physical chemistry involved 
in Urolithiasis and 24-hour urinary collection is consider integral for the selection 
of appropriate intervention to prevent kidney stone recurrences, the significance 
of the urinary profile, magnitude of their clinical effects and efficacy of selective 
treatment remains to be define.9-11 
  
 
 
 
   
AIM 
 Aim of the study was, to identify the differences in urinary profile of a stone 
former and matched member of the same family.  
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REVIEW OF LITERATURE 
Upper urinary tract stones are a significant cause of morbidity and 
resulting cost of treatment. The natural history of calcium urolithiasis has been 
difficult to establish. Several early studies addressed the natural history of 
calcium urolithiasis.1,2,12,13 The likelihood of forming another stone after the first 
episode is about 10% at 1 year, 30-40% at 5 year, 50-60% at 10 years and 
possibly 95-100% at 20 to 25 years.1-4 Consequently, strategies aimed at stone 
prevention are attractive.  
The goal of clinical and laboratory evaluation of patients with stone disease is 
to obtain information needed for management of patients presenting with stone 
and for prevention of further stones in these patients. Likewise, the identification 
of individuals at high risk of stone formation can improve the selection, evaluation 
and treatment of patients. On the other hand, the understanding of the 
mechanisms of idiopathic calcium nephrolithiasis is controversial because we are 
still unable to establish clear-cut cause-effect relationship between metabolic and 
physicochemical abnormalities and stone formation. A family history of stone 
formation substantially increases the risk of stone formation suggesting that diet 
and life style modifications may be useful in these healthy family members.14 
Encouragingly, the treatment arms of many of the randomized trials have shown 
dramatic reductions of 50% or more in recurrence rates.3,15-17 These reductions 
by medication or dietary interventions emphasize that recurrent stone disease is 
preventable.  
However, surgical treatments, although they remove the offending stone, do 
little to alter the course of the disease. With the recent advancement of ESWL 
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and endourological techniques in the surgical management of patients with stone 
disease there has been marked reduction of the morbidity in the management of 
stone patients. However there is decreased concern on the part of some 
practitioners and patients about prevention of stone formation. This is despite the 
increasing understanding of factors that promote stone growth and an increasing 
awareness of prevention of stone formation which is within the grasp of a 
practicing physician.  
Given the frequency with which a stone recurs, the development of a medical 
prophylactic program to prevent stone recurrences is desirable. With proper 
assessment and management of risk factors, physicians can alleviate stone 
formation in most patients and avoid expensive urological procedures. Some 
recommend comprehensive urinary metabolic work-up in recurrent stone formers 
and limited metabolic workup for the first time stone formers18,19 and consequent 
dietary modifications.20  
2.1. Epidemiology 
2.1.1 Prevalance 
The lifetime prevalence of kidney stone disease is estimated to be 1% to 
15%, with the probability of having a stone varying according to age, gender, 
race and geographic location.21 In the United States, the prevalence of stone 
disease has been estimated to be more than 12% in men and 6% in women.22,23  
Using data derived from the United States National Health and Nutrition 
Examination Survey dataset (NHANES II and III), Stamatelou et.al.24 showed a 
5.2% prevalence of kidney stone disease from 1988 to 1994, which was 37% 
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more than from 1976 to 1980 in which the prevalence was 3.8%. The increase in 
the prevalence of stone disease has been observed by others also.25-28 This 
apparent increase may reflect an actual increase in stone disease or it may stem 
from increased detection of asymptomatic stones discovered with the greater use 
and higher sensitivity of imaging studies.29 
2.1.2. Recurrence rates 
Early reports suggested that if left untreated the likelihood of forming 
another stone after the initial episode was 30% to 40% at 5 years.30 These 
figures from observational studies are similar to the recurrence rates in the 
control arms of recently published randomized trials.3,17 Many of the randomized 
trials have shown dramatic reductions of 50% or more in recurrence rates.3,15-17 
These reductions by medication or dietary interventions emphasize that recurrent 
stone disease is preventable.  
2.2. Factors affecting nephrolithiasis and their impact 
2.2.1. Non-dietary, 
2.2.2. Dietary, 
2.2.3. Urinary risk factors, 
2.2.4. Renal tubular damage and cellular dysfunction and 
2.2.5. Macromolecules 
2.2.1. Non-dietary 
a) Family history 
A family history of stone disease substantially increases the risk of stone 
formation suggesting that dietary and life style modifications may be useful in 
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these healthy family members. The risk of becoming a stone former is more than 
2.5 times in individuals with a family history of stone disease.14 A family history 
increases the risk of kidney stone passage independent of dietary risk factors.31 
This higher risk is likely due to a combination of genetic predisposition as well as 
similar environmental factors.29 Identification and characterization of families of 
recurrent stone formers is essential for the identification of unique genetic, 
environmental and metabolic factors that predispose individuals to recurrent 
calcium oxalate stone formation. A polygenic inheritance has been proposed to 
account for the tendency to calcium oxalate stone formation in families.32 While a 
number of genetic factors have been clearly associated with rare forms of 
nephrolithiasis, the information regarding genetic contribution to the common 
forms of stone disease is limited. 
b) Environmental factors 
Seasonal variation in stone disease is likely related to temperature by way 
of fluid losses through perspiration and perhaps by sunlight-induced increases in 
vitamin D formation. Individuals working in a hot environment appear to be at a 
higher risk for stone formation.33 The highest incidence of stone disease has 
been noted in the summer months, July through September, with the peak 
occurring within 1 to 2 months of maximal mean temperatures.34 In many 
situations, lack of access to water or toilet facilities may lead to lower fluid intake 
and with the resulting lower urinary volume there is an increased risk of stone 
formation. Thus it is likely that climatic and geographical conditions indirectly 
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influence the prevalence of stone disease through effects on temperature and 
possibly sunlight. 
c) Systemic disorders 
Although nephrolithiasis has traditionally been considered a renal 
disorder, overwhelming evidence suggests that it is in fact a systemic disorder. 
Primary hyperparathyroidism, renal tubular acidosis, and Crohn’s disease are 
well-described conditions that increase the risk of formation of calcium-containing 
stones. Primary hyperparathyroidism may be found in 5% of stone formers.35 
More recently, a number of other common conditions have been convincingly 
linked to nephrolithiasis. Increase in body size as assessed by weight, body 
mass index (BMI), or waistline measurements is associated with an increase in 
risk of stone formation independent of other risk factors, including diet.36 The 
magnitude of the increase in risk from BMI is higher in women than in men. For 
example, the risk of stone formation for individuals with a BMI greater than or 
equal to 30 compared to those with a BMI of 21 to 23 was 30% higher among 
men but nearly 50% higher among women. Weight gain also increases the risk of 
stone formation. A 35-lb weight gain since early adulthood increased the risk of 
stone formation by 40% in men and 80% in women.29 The mechanism or 
mechanisms for the increased risk associated with larger body size are unknown. 
A history of gout increases the likelihood of forming kidney stones, both uric 
acid and calcium oxalate. In a national health survey, individuals with gout were 
50% more likely to have a history of stones.37 When examined prospectively, a 
history of gout was associated with the double risk of stone formation, 
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independent of diet, weight and medication.39 Although the mechanism for this 
relationship is unknown, possibilities include insulin resistance and acid–base 
defects.  
More recently, diabetes mellitus was found to raise the risk of stone formation 
independent of diet and body size.40 Cross-sectionally, individuals with a history 
of type-II diabetes mellitus were 30% more likely to have a history of 
nephrolithiasis. Prospectively, a history of type-II diabetes mellitus increased the 
risk of stone formation by 30% to 50% in women but not in men. Irrespective of 
the aforementioned risk factors some patients need particular attention because 
of the specific risk factors summarized in Table-1. 
Table-1. Specific risk factors for stone formation.40 
 
• Start of disease early in life: <25 years 
• Stones containing brushite 
• Disease associated with stone formation 
Hyperparathyroidism 
Renal tubular acidosis (complete/partial) 
Jejunoileal bypass 
Crohn’s disease 
Intestinal resection 
Malabsorptive conditions 
Sarcoidosis 
Hyperthyroidism 
• Medication associated with stone formation 
Calcium supplements 
Vitamin D supplements 
Ascorbic acid in megadoses (>4 g/day) 
Sulfonamides † Triamterene † Indinavir †                                                                                                                                
  
2.2.2. Dietary factors 
The epidemic of stones of the upper urinary tract that has swept the 
developed nations of the world is closely correlated with rising affluence and 
increasing per capita expenditure on food.41 Two observations highlight the 
• Anatomical abnormalities 
associated with stone formation 
Tubular ectasia (MSK) 
PUJ* obstruction 
Calix diverticulum/calix cyst 
Ureteral stricture 
Vesicoureteral reflux 
Horseshoe kidney 
           Ureterocele 
 
 
 
 
† Noncalcium stones 
*Pelvi-ureteral junction 
 9
association between dietary factors and stone formation. First, the `stone boom', 
which corresponds to the dramatic increase in the incidence of stone disease in 
western industrialized nations after World War II, compared to the period during 
the war when animal protein was poorly consumed and malnutrition was the rule 
when the incidence of stone disease had declined.42 Second, the `stone clinic 
effect', a phenomenon described by the Mayo Clinic years ago to explain the 
reduction of stone recurrence in 66% of the patients after basic dietary advice.43  
The composition of the urine is influenced by dietary intake and several 
dietary factors have been proposed to modify the risk of nephrolithiasis. Nutrients 
implicated are calcium, animal protein,44 oxalate,45 sodium,46 sucrose,47 
magnesium,48 and potassium.49 Patients who develop stones often change their 
diet. Studies that retrospectively assessed diet may be hampered by recall bias. 
Other studies have examined the relation between diet and changes in the 
lithogenic composition of the urine, often using calculated relative 
supersaturation. However, the composition of the urine does not completely 
predict risk and not all the components that modify risk are included in the 
calculation of supersaturation (eg. urine phytate). Thus, prospective studies are 
best suited for examining the association between dietary factors and risk of 
actual stone formation.  
a) Calcium  
Albright F et.al.50 in 1953, defines the syndrome of idiopathic 
hypercalciuria consisting of normo-calcemia, low serum phosphorus level and 
increased urinary calcium excretion in the absence of clearly established causes 
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of hypercalciuria. Since then, numerous studies have been performed in order to 
distinguish between increased intestinal calcium absorption (‘‘absorptive’’ 
hypercalciuria), diminished renal tubular reabsorption of calcium (‘‘renal leak’’ 
hypercalciuria), or increased bone resorption (‘‘resorptive’’ hypercalciuria) as the 
primary cause of idiopathic hypercalciuria.51 Whatever the primary cause, the 
available data suggests that the syndrome of idiopathic hypercalciuria always 
includes features of intestinal hyper-absorption and reduced tubular reabsorption 
of calcium,52 most likely caused by a mutual imbalance of two calciotropic 
hormones, that is calcitriol (relatively up-regulated) and parathyroid hormone 
(relatively down regulated).53 
Low calcium or high calcium intake— the evidence 
Based on the key features of idiopathic hypercalciuria, that is increased 
intestinal absorption and urinary excretion of calcium, regardless of the physico-
chemical meaning of increased urinary calcium, physicians for many decades 
thought that dietary calcium increases the risk of stone formation.54 
Although dietary calcium had been strongly suspected of raising the risk of 
stone disease, men with a higher intake of dietary calcium actually had a lower 
risk of incidental nephrolithiasis independent of other risk factors. This inverse 
association has been confirmed in two other prospective studies55,56 and in an 
updated analysis.57 Although the mechanism of this effect is unknown, low 
calcium intake is known to increase oxalate absorption and urinary excretion and 
individuals with higher calcium intake have lower 24-hour urine oxalate 
excretion.58 Moreover, even if calcium intake is highly restricted (daily calcium 
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intake 2 mg/kg body weight), a number of patients with idiopathic hypercalciuria 
still excrete more calcium than they eat and therefore get into negative calcium 
balance.59 Indeed, osteopenia has been found in many patients with idiopathic 
hypercalciuria, and some studies clearly indicate that a low calcium diet 
contributes to reduced bone mass.60 
Curhan GC et.al.14 has shown that low dietary calcium intake may increase 
the risk of stone formation even among individuals with a family history of stones. 
The above-mentioned observational data was subsequently confirmed in a 
randomized trial by Borghi et.al.3 that compared a low calcium diet (400 mg/d) to 
a diet containing 1200 mg/d of calcium along with low sodium and low animal 
protein intake in men with absorptive hypercalciuria type-II and calcium oxalate 
stones. The calcium oxalate supersaturation declined in all patients over the 
whole study period but was consistently lower in hypercalciuric male stone 
formers randomized to a diet restricted in animal protein and salt but with normal 
calcium content (1200 mg/day) compared with patients consuming a low-calcium 
(400 mg/day) diet (Figure-1). Interestingly the rate of recurrence fell by 50% in 
the higher calcium intake group. Unfortunately, the effect of the two study diets 
on urinary citrate was not elucidated. While some authorities still question 
whether a high calcium diet reduces the risk of stone formation, overwhelming 
evidence shows that calcium restriction is not beneficial and may in fact be 
harmful, both by promoting stone formation and accelerating bone loss.  
 12
0
2
4
6
8
10
12
1 2 3 4 5 6
Years
R
el
.s
up
er
sa
tu
ra
ti
Low Ca
Normal Ca/Low Prot/ Low Na
 
 
 
 
Despite similar bioavailability, the impact of supplemental calcium appears to 
be different from dietary calcium. In an observational study of older women, 
calcium supplement users were 20% more likely to form a stone than were 
women who did not take supplements, after adjusting for dietary factors.55 In 
younger women and men there was no association between calcium supplement 
use and the risk of stone formation.61,56 The discrepancy between the risks from 
dietary calcium and the risks from calcium supplements may be due to the timing 
of calcium intake. In these studies, calcium supplements were often taken 
between meals, which would diminish binding of dietary oxalate. The recently 
published Women’s Health Initiative randomized trial also demonstrated 17% 
increase risk of stones with calcium supplementation.62 However, these results 
should be interpreted cautiously because the participants were instructed to take 
    0             1             2              3             4              5
Figure-1: Relative calcium oxalate supersaturation (SSCaOx) of 24 hr urine from male 
idiopathic calcium stone formers on either normal calcium, low animal protein/low-salt or 
low-calcium diet. (Redrawn from Borghi L, Schianchi T,Meschi T, et al. Comparison of two 
diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 
2002;346;77–84.) 
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their supplements with meals, and the supplements contained both calcium and 
vitamin D. 
b) Oxalate 
The most likely reason why stone recurrences are more frequent on a low 
calcium diet is reciprocal hyperoxaluria that is increased intestinal oxalate 
absorption caused by reduced binding of oxalate due to low dietary calcium63or 
mal-absorption syndromes, in which calcium complexion with unabsorbed dietary 
fat renders dietary oxalate more easily absorbed and leads to hyperoxaluria.64 
Also the alteration in colonic permeability to oxalate (induced by un-absorbable 
bile salts, also seen in resection of terminal small bowel) have been proposed to 
explain the intestinal hyper-absorption of oxalate in patients with intestinal 
hyperoxaluria.65 The role of dietary oxalate in the pathogenesis of calcium 
oxalate nephrolithiasis is unclear.66 The proportion of urinary oxalate derived 
from dietary oxalate is controversial; estimates range from 10% to 50%.66  In 
addition to the gastrointestinal absorption of dietary oxalate, urinary oxalate is 
also derived from the endogenous metabolism of glycine, glycolate, 
hydroxyproline, and vitamin C.29 Due to variable and often low bioavailability, 
much of the oxalate in food may not be readily absorbed. Bioavailability of 
oxalate in most foodstuffs is very low (0.01mmol/100g),67 so practically dietary 
intake of excessive oxalate is relatively uncommon even in stone formers.42 
Nonetheless, studies have shown that the dietary contribution of urinary oxalate 
is higher in recurrent calcium oxalate stone formers.64 Up to one third of patients 
with calcium oxalate nephrolithiasis may have increased absorption of dietary 
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oxalate.68 In some cases, a deficiency of oxalate degradation by the bacterium 
Oxalobacter formigenes in the gut could be the culprit.66 In a short-term study in 
healthy volunteers on a highly standardized dietary regimen (controlled for total 
calories and intakes of fluid, protein, salt, calcium, and oxalate), the author 
demonstrated that a 20-fold normal oxalate load (2220 mg/day) induces 
significant hyperoxaluria (average 69 mg/day) and in some subjects even 
passage of calcium oxalate crystal aggregates when the diet contained 1200 mg 
of calcium per day. Average urinary calcium amounted to 128 mg per day.69 
When applying the protocol in the same subjects with the identical oxalate load, 
but with 3850 mg/day of calcium, hyperoxaluria disappeared (average 29 
mg/day) and urinary calcium increased (average 291 mg/day), but no crystal 
aggregates were passed.69 This indicates that increases in urinary oxalate 
carries an increased risk for crystal aggregation of calcium oxalate than 
increases in urinary calcium even in non-stone formers. Very large amounts of 
oxalate can be tolerated if they are bound at the intestinal level by a high amount 
of calcium ingested simultaneously.69 These data were confirmed by Holmes 
et.al.70 who found that the bioavailability of oxalate and urinary oxalate excretion 
were reduced by increasing the diet’s calcium content. In their most recent study, 
Borghi et. al.3 also found that urinary oxalate decreased, by an average of 80 
µmol per day, on a normal calcium/low animal protein/low salt diet, compared 
with a low-calcium diet that increased urinary oxalate by an average of 60 µmol 
per day. Holmes et.al.70 also demonstrated that dietary oxalate makes a much 
larger contribution to urinary oxalate excretion than previously recognized, 
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reaching an average of 53% on a diet containing 250 mg of oxalate and 391 mg 
of calcium per day. The problems to advise an oxalate-restricted diet for calcium 
stone patients are 
1. Oxalate is found in many foods, thus a low-oxalate regimen will not be 
palatable or acceptable to all patients.70 
2. Measurements of the oxalate content of foods vary considerably because of 
analytical differences and/or uncertainties.71 
3.  Considerable variation of oxalate absorption exists between individuals.70 
It therefore appears more appropriate to first advice patients on a sufficient 
calcium intake simultaneously ingested with food in order to avoid increases in 
urinary oxalate excretion. Nevertheless, efforts to restrict dietary oxalate should 
be made because they also can be sufficiently effective to limit the degree of 
calcium-oxalate interaction in the bowel. Though, the value of reducing dietary 
oxalate intake in order to lower urinary oxalate excretion has been questioned, a 
recent study demonstrated that urinary oxalate does not increase even on a low 
calcium diet, when oxalate is restricted simultaneously.73 The utility of dietary 
modification is supported by the observation that no pharmacological therapy has 
been consistently successful in reducing urinary oxalate excretion. The dietary 
modification is particularly effective in patients who are ingesting a self-selected 
high dietary oxalate.42  
The impact of dietary oxalate on risk of stone formation has not yet been 
studied prospectively because of the lack of sufficient and reliable information on 
the oxalate content of many foods. However, recent reports using modern 
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approaches to measure the oxalate content of food73,74 have opened the 
possibility of these studies. 
c) Protein 
Anderson et.al.75 had showed strong correlation between affluence and 
nephrolithiasis. Lower urinary tract stones seen in various countries in Southeast 
Asia were known to be related to protein malnutrition. Due to high dietary protein 
intake an increased risk of upper tract nepholithiasis has been noted in affluent 
societies.75 The relationships among affluence, diet and stone were particularly 
very impressive because they could be demonstrated within single nations as 
well as across heterogeneous societies.76 For example, in northern and western 
regions of India, animal protein intake is approximately 100% greater than the 
southern and eastern regions. The risk of upper tract stone formation as 
estimated from hospitalization rates was 23.9/1000 admissions in north and west 
compared with 5.9/1000 admissions in the south and east.42  
Effect of diet protein in clinical studies 
Lithogenic effect of protein diet is not established in all instances. Some 
studies have failed to show that there is a difference in dietary intake between 
stone formers and controls.77 In a large study Wasserstein and colleague78 found 
that patients with recurrent nephrolithiasis consumed a diet that was similar in its 
composition to that of a large population of case controls. While there was a clear 
linear relationship between the dietary protein intake as estimated by excretion of 
urinary urea nitrogen and urinary calcium, the nature of this relationship 
suggested that patients with recurrent nephrolithiasis are more sensitive to the 
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calciuric action of protein. This was because any increment in dietary protein 
elicited a proportionately greater increase in calciuria in the patients with 
recurrent nephrolithiasis compared with controls (Figure-2). The underlying 
mechanism whereby dietary protein leads to hyper-calciuria and the reason for 
the specific increased sensitivity of patients with recurrent nephrolithiasis to the 
hypercalciuric action of dietary protein remains unknown. The effect may be due 
to high protein intake of animal origin contributing to hyperuricosuria due to the 
purine overload, to hyperoxaluria due to the higher oxalate synthesis, increased 
acidity of the urine which directly inhibits the calcium absorption from the distal 
nephron and to hypocitraturia due to the higher tubular reabsorption of citrate due 
to low urinary pH.79,80 The citrate chelates urinary calcium, reducing the level of 
urinary ionized calcium, and citrate may inhibit calcium oxalate crystal growth.81 
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Figure-2: Correlation between urinary calcium excretion and urinary urea nitrogen (an 
index of dietary protein intake) in patients and controls. The greater slope in the cases 
versus the controls suggests a greater sensitivity to the calciuric effect of protein in the 
cases. (Redrawn from: Wasserstein AG, Stolley PD, Soper KA. et.al. Case control stuey 
of risk factors for idiopathic calcium nephrolithiasis. Miner. Electrolyte.Metab.1987;13:85.) 
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Wasserstein et.al.78 had shown that the restriction of dietary protein in 18 
patients with recurrent calcium stone formation from 96±5 to 60±65 g/day 
resulted in significant rise in urinary citrate excretion, from 450±44 to 565±51 
mg/day. In the subgroup of hypercalciuric patients (n=11), reduction of dietary 
protein from 101±4 to 60 to 65 g/day produced even more marked elevation of 
citrate excretion (451±49 to 632±58 mg/day). Additionally, protein-induced 
hypercalciuria may be caused by higher bone resorption and lower tubular 
calcium reabsorption to buffer the acid load, and also by the elevated filtered load 
of calcium and by the presence of non-reabsorbable calcium sulfate in the tubular 
lumen.78 An acute moderate protein restriction reduces urinary oxalate, 
phosphate, hydroxyproline, calcium and uric acid and increases citrate excretion 
as recently reported.82 In population whose intake of dietary protein is reduced or 
absent such as vegetarians, the risk of nephrolithiasis is markedly reduced.42 In 
studies carried out in Great Britain, the prevalence of stone formation was 
threefold less in a group of vegetarians than in the general population. This 
protective effect of vegetarianism is present even though increased dietary 
oxalate may result from high oxalate vegetable intake.83 
d) Citrate 
Low urinary citrate excretion is an accepted risk factor for calcium 
nephrolithiasis because it reduces urinary supersaturation by complexing calcium 
ions. In addition, it inhibits growth and aggregation of calcium oxalate and 
calcium phosphate crystals.84 By complexing calcium ions, citrate also enhances 
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the inhibitory activity of Tamm-Horsfall glycoprotein towards calcium oxalate 
crystal aggregation.85,86  
Accepted risk factors for hypocitraturia (<1.70 mmol/day) are distal renal 
tubular acidosis (complete or incomplete) as cytosolic acidification enhances the 
uptake of citrate from proximal convoluted tubule,87 acquired metabolic acidosis 
caused by chronic diarrhoeal states, intracellular acidosis caused by thiazide 
induced potassium depletion, high sodium intake which induces mild metabolic 
acidosis caused by increased bi-carbonaturia, excess intake of animal protein 
(sulfur-containing amino acids), decreased intake of alkali, and primary 
gastrointestinal mal-absorption of citrate84 In a study of male patients with 
recurrent idiopathic calcium nephrolithiasis undergoing 3-day ammonium chloride 
loading while under free-choice diet, Hess et.al.88 found that 33% had either low 
citraturia (<2.12 mmol/day) or overt hypocitraturia (<1.70 mmol/day). Incomplete 
renal tubular acidosis occurred in 91% and gastrointestinal alkali absorption less 
than 15 mEq per day in 18% of these patients. In addition, high urinary citrate 
excretion was correlated with more dietary vegetable fibers, a source of alkali 
and with urine volume.88 The latter correlation is possibly because proton 
secretion along the proximal tubule is flow-dependent, and thus low urine flow 
would induce mild metabolic acidosis and diminish urinary citrate excretion.82 On 
the other hand, administration of bicarbonate-rich mineral water89 and orange 
juice90 increases urinary citrate excretion. Unfortunately, no urinary citrate 
measurements are available from the two prospective randomized controlled 
trials on dietary treatment of calcium nephrolithiasis.5,91 
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e) Other nutrients 
1. Role of Dietary Sodium in the pathogenesis of Hypercalciuria 
There is a close relationship between renal tubular calcium and sodium 
handling; most factors that promote natriuresis tend to stimulate urinary calcium 
excretion.92 Calcium reabsorption parallels the sodium in the renal tubule.93 The 
only means to produce a sustained increase in urinary sodium excretion is to 
increase sodium intake. Dietary sodium may also be a risk factor for 
hypercalciuria and therefore for calcium oxalate nephrolithiasis. Every 100 mmol 
increase in dietary sodium increases urinary calcium excretion by 25 mg.94 The 
adverse effects of a high NaCl intake and the resultant higher calcium excretion 
have been well documented by many investigators.46,95,96 In a previous analysis, 
multiple regression suggested that a high NaCl intake (16 g/day) was the single 
variable that was predictive of risk of low bone mineral density in 85 calcium 
stone forming patients (odds ratio: 3.8) after adjustments for age, weight, body 
mass index, duration of stone disease, calcium and protein intakes and urinary 
calcium citrate and uric acid.97 A high NaCl intake is expected to lower citrate 
excretion as well.98 Frusemide and Bumetanide administration produces 
concomitant calciuria and natriuresis by inhibiting calcium and sodium transport 
in the thick ascending limb of Henle’s loop.97 Lau et.al.100 has showen in patients 
with idiopathic hypercalciuria, the renal hypercalciuric ingested 50 mEq/day more 
sodium than the diet-dependent hypercalciuria patients. Restriction of dietary 
sodium intake produces a predicable fall in urinary calcium excretion and lead to 
the re-categorization of patients with so-called renal-hypercalciuria to diet-
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dependent hypercalciuria. It leads to the proposal that modification of the dietary 
sodium intake may be a rational form of therapy in these patients. The 
hypercalciuric action of dietary sodium is markedly seen in recurrent calcium 
stone formers.42 
Controlled studies failed to show that the general population of patients with 
recurrent calcium oxalate nephrolithiasis ingests greater mean dietary sodium 
than controls.77 It also reinforces the idea that undue sensitivity to calciuric stimuli 
is present in patients with recurrent calcium stone formers.42 
2. Vitamin C 
The effect of large doses of vitamin C in increasing urinary oxalate 
excretion is controversial.101,102 Vitamin C (ascorbic acid) can be metabolized to 
oxalate; thus higher vitamin C intake could increase the risk of calcium oxalate 
stone formation. Curhan GC et.al.103 has showen that the intake of vitamin C was 
not associated with risk of kidney stones in women. Traxer OA et.al104 has 
demonstrated that the consumption of 1000 mg of supplemental vitamin C twice 
daily increases urinary oxalate excretion by 22%. An observational study in men 
found that those who consumed ≥1000 mg/day of vitamin C had a 40% higher 
risk of stone formation compared with men who consumed less than 90 mg/day 
(the recommended dietary allowance).57 This relationship was observed only 
after accounting for dietary potassium intake. Although restricting dietary vitamin 
C does not seem appropriate (as foods high in vitamin C are also high in 
inhibitory factors such as potassium), a calcium oxalate stone former should be 
encouraged to avoid vitamin C supplements.  
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3. Vitamin B6 
Vitamin B6 is a cofactor in oxalate metabolism and vitamin B6 deficiency 
increases oxalate production and urinary oxalate excretion. Although high doses 
of supplemental vitamin B6 may be beneficial in selected patients with type-1 
primary hyperoxaluria, the use of vitamin B6 in other settings remains unclear. 
Based on observational data, high intake of vitamin B6 may reduce the risk of 
kidney stone formation in women103  but not in men.105 
Numerous other factors have been studied and implicated in the development 
of stone formation but many of the associations with risk varies with by age, sex, 
or BMI. Taylor EN et.al.57 has observed an increased risk of stone formation 
among men with higher intake of animal protein and BMI less than 25. 
4. Potassium 
An epidemiological study has reported that lower the potassium intake,    
(≤74 mmol/day) higher the relative risk of stone formation61 whereas potassium 
supplementation decreases calcium excretion49 and many potassium-rich foods 
increase urinary citrate due to their alkali content. Such an effect can be ascribed 
to an increase in urinary calcium and a decrease in urinary citrate excretion 
induced by a low potassium intake.49 Recently, phytate was also found to reduce 
substantially the likelihood of stone formation in younger women.56  
5. Magnesium  
Magnesium complexes with oxalate, thereby potentially reducing oxalate 
absorption in the gastrointestinal tract and decreasing calcium oxalate 
supersaturation in the urine. A few randomized trials have examined the effect of 
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magnesium supplementation on stone recurrence. However, magnesium was 
given in combination with other compounds (eg, thiazide diuretic or potassium 
citrate) and the dropout rates were high. Currently, it is uncertain whether 
magnesium supplementation has an independent beneficial effect. In prospective 
observational studies, higher dietary magnesium was associated with a 30% 
lower risk of stone formation in men,57 but not in women.55,56  
6. Fluid intake and beverages  
When the urine output is less than 1 L/d, risk of stone formation is 
markedly higher (Figure-3).105 
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Observational studies55,56,61 and a randomized controlled trial107 have 
demonstrated the importance of fluid intake in reducing the likelihood of stone 
formation. A high fluid intake is a very important goal to reduce urine 
supersaturation. In a large prospective study of men, who had no history of 
kidney stones, an inverse association between fluid intake and the risk of urinary 
Stone forming Range
Figure-3: Relationship between the relative probability of stone formation based on analysis of 
urinary constituents and the 24 hour urinary volume in normal individuals. (Redrawn from: 
Frank M, DeVries A, Lazebnik J et.al. Epidemilogical investigations of Uroloithiasis in Israel. J 
Urol;81:497-504:1959.) 
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stone formation was observed during 4 years of follow-up.61 After adjustment for 
other potentially confounding variables in the multivariate analysis, the relative 
risk for men decreased significantly from 1.0 in the lowest quintile (<1,275 ml/ 
day fluid intake) to 0.71 in the highest quintile (>2,538 ml/day fluid intake).61 This 
finding in men was consistent with the results of a long-term prospective study 
among women where the risk of stone formation was inversely related to fluid 
intake.55 In the multivariate model, the relative risk for women with the highest 
fluid intake was 0.61 as compared with those with the lowest intake (1.0), a 39% 
reduction in risk. In a prospective randomized control trial involving first stone 
episode patients who were randomized to increase water intake to at least 2 
lt/day has shown lower rates of recurrence (12%) compared to those without 
(27%) and the time interval until the recurrences occurred was significantly 
longer in patients on high water intake. In this study patients were not on any 
drug therapy or dietary change, so that the effect was exclusively explained by 
the selective increase in urinary volume.107 The study confirms that an increase 
in fluid intake to assure a consistent urinary volume of at least 2 l/day is the initial 
therapy for the prevention of stone recurrences.  
To what extent the hardness and mineral composition of water affects stone 
formation remains controversial.108-110 As the calcium content of drinking water 
increases, calcium excretion increases but oxalate excretion falls109,111 Water with 
a large amount of bicarbonate may increase citrate excretion109 and magnesium 
content may favourably alter citrate and magnesium excretion.112 Based on these 
findings, there is still no definite evidence that hard water rich in calcium and 
 25
magnesium, is more lithogenic than soft water. Fluid therapy could be harmful by 
dilution of urinary inhibitors with a high urine volume that may paradoxically 
increase the risk of stone formation.42 However studies of the formation product 
ratio and the activity product ratio of urine diluted in-vitro and in-vivo failed to 
demonstrate an increase in the risk of stone formation with increasing urinary 
dilution.113 
Despite previous beliefs to the contrary, observational studies have found that 
Caffeinated, decaffeinated coffee, tea (risk reduction of 8-10%) beer, and wine 
(risk reduction of 59%) are associated with a reduced risk of stone formation. 
114,115 It was speculated that the protective effects of coffee, tea and wine were 
caused by urinary dilution, determined by the ability of caffeine and alcohol to 
inhibit antidiuretic hormone. Therefore, the decreased risk for decaffeinated 
coffee might have been conferred by another mechanism. Although citrus juices 
theoretically could reduce the risk of stone formation,116 orange juice 
consumption was not associated with stone formation and grapefruit juice intake 
was associated with a 44% higher risk.114,115 Grapefruit juice is known to have a 
number of effects on intestinal enzymes but the mechanism for the observed 
increased risk is unknown.29 Previously studies had suggested an increased risk 
for soda consumption and unadjusted results from observational studies also 
suggested an increased risk. However, after controlling for other dietary 
components, consumption of soda (including soda with caffeine, soda without 
caffeine, diet soda and conventional sweet soda) was not associated with the risk 
of stone formation.114,115 Although skim and whole milk were not associated with 
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risk in the observational studies, probably because these studies adjusted for the 
intake of dietary calcium, milk intake likely reduces the risk of calcium kidney 
stone formation. In summary, these results must still be interpreted with caution 
until adequate long-term randomized trials of dietary interventions are performed. 
2.2.3. Urinary factors: The principle of supersaturation 
Supersaturation is the driving force behind crystal formation. When the 
solution is supersaturated with lithogenic substance crystallization occurs and 
thus nucleation, crystal growth, crystal agglomeration and stone growth. The 24-
hour urine chemistries provide important information about uro-metabolic 
abnormalities and thus direct therapeutic recommendations for prevention. 
Traditionally, urine results have been categorized as ‘‘normal’’ or ‘‘abnormal’’ and 
potential diagnosis from a metabolic evaluation of a calcium stone former are 
shown in Table-2.  
Table-2: Abnormalities from uro-metabolic evaluation of calcium stone former 117 
• Low urinary volume (<2 L/d) 
• Hyperoxalauria (>40 mg/d) 
• Hyperuricosuria (>750 mg/d) 
• Hypocitraturia (<300 mg/d) 
 
 
 
Recently Curhan29 has emphasized two important points. 
1. The urine values are continuous variables so the ‘‘normal’’ or ‘‘abnormal’’ 
categorization is arbitrary.  
2. Stone formation is a disorder of concentration, not just the absolute amount 
excreted.  
 
• Hypercalciuria (>250 mg/d in women; 
>300 mg/d in men) 
o Types I, II, and III absorptive 
hypercalciuria 
o Renal leak hypercalciuria 
o Resorptive hypercalciuria 
• Hypomagnesuria <3mmol/L 
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In 1978, Pak et al.2 developed an ambulatory protocol to identify the 
underlying cause of Urolithiasis. This protocol provided a definitive diagnosis in 
95% of the patients.3,4 This ambulatory instrument made diagnostic separation 
and classification of urolithiasis more accessible and more practical for all 
patients. The ability to distinguish among the underlying physiologic disturbances 
allowed the application of a selective treatment programme on the basis of 
correction of the specific physiologic derangement. Over the years, selective 
therapies were formed that contain three different components: high fluid intake, 
specific diet, and medication. 
2.2.3.(1). Solubility and supersaturation 
There is a maximum to the amount of a compound that can be kept in 
stable solution (at equilibrium). This is defined by its solubility or equilibrium 
concentration product.118 When the amount in solution exceeds the solubility, 
supersaturation results. There is a drive to remove the excess by crystallization. 
This drive can be manipulated in two ways: changing the pool available for 
precipitation and changing the solubility.118 
2.2.3.(2). Crystallization as basis of Urolithiasis 
Urinary stones are composed of crystalline material usually associated 
with a matrix of organic material. Irrespective of the type of stone, crystallization 
is a first step in stone formation. The solubility of a salt depends upon its crystal 
characteristics and its activity in solution. The first depend on the crystal 
structure, crystal-solute interactions and crystal size. Small crystals are less 
stable and their solubility is increased.118 Below the critical nucleus size of 0.1 
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μm, crystals are unstable and they prefer to dissolve rather then grow further. 
(Kelvin or Ostwald-Freundlich effect).119 The rate at which particles of this size 
form and survive is the nucleation rate. Stabilization of nuclei by adherence to a 
different solid phase (heterogeneous nucleation)6 and de-stabilization by 
adherence with the substances (inhibition of nucleation) strongly influence the 
nucleation rate in urine. The available pool is also affected by chelation and 
changing protonation state (pH effect).119  
For compounds that have an acid dissociation constant, pKa, within the pH 
range for urine, 5 to 8, the protonation state can vary. Thus uric acid (pKa 5.35) 
is prone to precipitate in acidic urine and is more soluble in alkaline urine. 
Changes in pH also affect other urine compounds. In alkaline urine, citrate is 
more in its triple de-protonated form, which is more effective in preventing 
crystallization.119 
2.2.4. Renal tubular damage and cellular dysfunction 
Super-saturation is the driving force behind crystal formation. It can, 
however, result only in the formation of crystals which can be harmlessly 
expelled. For stone formation, crystals should be formed and retained in the 
kidney which is a rare occurrence.120,121 Crystalluria is common while stone 
formation is not. The retention risk depends on crystal size and surface, flow 
dynamics, urinary tract-dimensions and cell-surface characteristics. Lethal 
epithelial cellular injury promotes crystal nucleation, aggregation and retention. 
Sub-lethal injury or dysfunctional cells may produce ineffective crystallization 
modulators and localized areas of supersaturation in the interstitium (Figure-4). 
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The former will affect crystallization in the urine while the latter may cause 
precipitation in the interstitium and development of Randall’s plaques.122 He 
suggested that interstitial sub-epithelial deposits of calcium phosphate or calcium 
carbonate arising from pathological conditions of the renal papilla eroded through 
the papillary surface forming a type-I lesion. He further suggested that excessive 
urinary supersaturation in association with tubular cell death resulted in crystal 
deposition in the collecting ducts producing a type-II lesion. Both types of lesions 
acted as foci for further stone growth in the pelvis or papillary ducts.123 Randall 
proposed a theory in which both urinary supersaturation and renal tubular 
damage play a part in stone formation. 
 
 Figure-4: Schematic presentation of relationship between various factors, which lead to formation of idiopathic renal stones. Crystals that are not expelled with the urine induce production of crystallization modulators and may 
eventually lead to cellular dysfunction and degradation and thus hetrogenous nucleation. Cell injury also promotes 
interstial inflammation, which is likely involved in crystal erosion to papillary surface and thus stone nidus. 
(Redrawn from Khan SR.Renal tubular damage/dysfunction: key to the formation of kidney stones Urol. Res. 
2006;34: 86–91) 
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2.2.5. Role of macromolecules 
 
The potential role of intra-crystalline proteins and lipids (macromolecules) 
in stone genesis has prompted studies to determine whether Tamm–Horsfall 
glycoprotein (most abundant protein in healthy human urine) is part of the 
organic matrix of CaOx crystals. Proponents argue that macromolecules are the 
real key molecules for stone inhibition.124 
A macromolecule containing multiple calcium binding sites will more strongly 
bind to growth sites where the density of calcium ions available for binding is 
greater.125 Urine contains numerous compounds like citrate, magnesium and 
macromolecules that can inhibit crystal growth. In whole urine macromolecules 
with the highest affinity for the growth sites contribute most to the growth 
inhibition. Tamm-Horsfall and nephrocalcin are potent inhibitor of calcium oxalate 
monohydrate crystal aggregation, but not growth.126 Osteopontin and uropontin 
have been shown to inhibit nucleation, growth, and aggregation of calcium 
oxalate crystals as well as to reduce binding of crystals to renal epithelial cells in 
vitro.127 
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MATERIALS AND METHODS 
 This study was conducted from April 2006 to January 2008 after taking 
approval from the institutional review board.  
3.1. Design of the study 
 This was a prospective matched Case-Control study. Informed consent 
(Annexure-i) for recruitment was obtained after a complete urological history 
(Annexure-ii) followed by serum and urinary examination. Seventy-eight subjects 
were recruited for the study (39 cases and 39 matched controls). Only patients 
from Tamilnadu were included in the study.  
3.2. Selection criteria 
3.2.1. Inclusion criteria for cases 
• Eighteen years or older in age, 
• Patients who had renal or ureteric stones with normal renal function. 
3.2.2. Exclusion criteria for cases 
• Patients with bladder stone, 
• Endocrine abnormality, 
• Anatomic urinary tract abnormality associated with stone formation, 
• History of bowel disease or resection predisposing to stone formation, 
• Medication and diseases associated with stone formation. 
3.2.3. Inclusion criteria for controls 
• Eighteen years or older in age, 
• Same gender as of the patient,  
• First degree relation with the patient, 
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• Diet matched relative–at least consuming two out of three major meals 
together, 
• No nephrolithiasis or history of stone disease, 
• Living in the family with the patient in the same house for at least last 5 
years. 
 Dietary matching was done with the help of the Dietary Department. 
3.2.4. Exclusion criteria for controls 
• Those with urolithiasis or history of urinary stone disease, 
• Endocrine abnormality associated with stone formation, 
• History of bowel disease or resection predisposing to stone formation, 
• Medication and diseases associated with stone formation. 
3.3. Parameters studied 
3.3.1. Serum analysis 
1. Calcium,  
2. Phosphorus,  
3. Uric acid,  
4. Albumin–globulin ratio,  
5. Sodium,  
6. Potassium and  
7. Bicarbonate. 
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3.3.2. Urinary analysis 
1. Calcium, 
2. Oxalate, 
3. Uric acid, 
4. Citrate, 
5. Magnesium,  
6. Creatinine, 
7. Urinary volume and 
8. Urinary pH. 
3.3.3. Presence of stone disease in controls was ruled out by X-ray and 
ultrasound of the kidney-ureter-bladder region. 
3.4. Urinary collection  
 The bladder was emptied at 6 AM. All the urine voided after that for the 
next 24 hours including the 6 AM void of the next day was collected. This 
procedure was explained to each case and control in detail to ensure proper 
collection of urine. Ambulatory 24-hour urinary analysis was done on two 
consecutive days. The first 24-hour urinary collection for analysis of urinary 
calcium and oxalate was done in a container with 10 ml of 6mmol of hydrochloric 
acid to prevent precipitation of calcium and oxalate salts and also prevents 
oxidation of ascorbic acid to oxalate. The second day collection, for urinary pH, 
uric acid, citrate, magnesium and creatinine was done in a container with 10 ml 
of 0.3mmol of sodium-azide, to prevent bacterial growth. Urinary volume was 
calculated averaging the urinary volume collected on the two consecutive days. 
24 hour urinary analysis 
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 There was no dietary restriction and 24-hour urinary samples were 
collected while on their regular diet at home. Urinary 24-hour sample collection 
was done before any intervention for urolithiasis.   
 Table-3 shows the laboratory values for the various test parameters, 
which were obtained from our institutional nomogram. Urinary abnormalities were 
hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia and 
hypomagnesuria. 
Table-3: Laboratory values for serum and urinary parameters. 
 
       Ambulatory normal serum values                           Values 
Calcium                          8.3-10.2 mg/dl 
Phosphorus                          2.5-4.6 mg/dl 
Uric acid                          4.0-7.0 mg/dl 
Albumin-globulin ration                          1.0-1.8 
Sodium                          135-145 mEq/L 
Potassium                          3.5-5.0 mEq/L 
Bicarbonate                          22-29 mmol/L 
       Ambulatory 24-hr urinary values                             Values  
Low urinary volume                          ≤ 1500 ml 
Hypercalciuria                          >300mg for male   
      >250mg for females 
Hyperoxaluria                          >40mg 
Hyperuricosuria                          >700 mg 
Hypocitraturia                          <250 mg 
Hypomagnesuria                          <3mmol 
Urinary creatinine                           1-2 gm 
Urinary pH                           5.5-6.5 
 
 
3.5. Statistical analysis 
 Data was entered in a spreadsheet, MS EXCEL and analyzed using 
Statistical Package for the Social Sciences, version 15.0 (SPSS 15.0) software. 
All continuous variables were summarized using mean and standard deviation, 
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while the categorical variables were summarized using frequencies and 
percentages. The value of each urinary constituent was compared using Mc-
Nemar test, to test the difference between cases and their matched controls.  
 Mc-Nemar test is used to analyze Case-Controls studies, where each 
case and control is matched. Here we assess matched pairs with respect to one 
dichotomous variable. If there is no association between the risk factor and the 
disease, we would expect the number of pairs where cases are exposed to the 
risk factor but control is not to equal the number of pairs where the controls are 
exposed to the risk factor but the case do not. A p value < 0.05 was considered 
as statistically significant. 
3.6. Analytic procedures used for serum and urinary measurements 
 All the serum and urinary parameters were measured on Olympus      
auto-analyzer machine. 
3.6.1. Calcium:  
      Method- Colorimetric, chemical end point method, for serum and urine 
analysis 
Principle- Calcium forms a purple colored complex with O-cresol-
phenolphthalein in alkaline medium. Intensity of color measured at 540 nm is 
directly proportional to the concentration of calcium in the sample. 
3.6.2. Phosphorus 
     Method - Colorimetric, Chemical end point method, for serum analysis. 
     Principle- Inorganic phosphorus reacts with ammonium molybdate and          
sulphuric acid (H2So4) to give phospho-molybdate colored complex. Intensity 
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of color measured at 340 nm is directly proportional to the phosphorus 
concentration in the sample. 
3.6.3. Uric acid 
      Method- Colorimetric, Enzymatic end point method, for serum and urine 
analysis. 
Principle- Hydrogen peroxide is formed when uric acid reacts with oxygen in 
presence of an enzyme oxidase. Hydrogen peroxide reacts with 4-
aminophenazone in a series of enzymatic reactions to give a red-violet 
colored product. Intensity of the color is directly proportional to the uric acid 
concentration in the sample. 
3.6.4. Oxalate 
Method- Colorimetric, Enzymatic end point method (quantitative). 
 Principle- Hydrogen peroxide is formed when oxalate reacts with oxygen in 
presence of an enzyme oxidase. Hydrogen peroxide reacts with 3-methyl-2-
benzothiaezoline hydrazone and 3-dimethyl amino-benzoic acid in a series of 
reactions to give colored complex. Intensity of color measured at 590 nm is 
directly proportional to the concentration of oxalate in the sample. 
3.6.5. Citrate 
 Method- Manual, Colorimetric, Chemical end point method. 
Principle- Citrate reacts with alkaline pyridium in the presence of acetic 
anhydride to produce colored complex. Intensity of color measured at 428 nm 
is directly proportional to the concentration of citrate. 
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3.6.6. Magnesium 
 Method- Colorimetric, Chemical end point method. 
 Principle- Magnesium ion reacts with xylidyl blue in alkaline medium to form a 
purple colored compound. Intensity of the color is directly proportional to the 
concentration of magnesium in the sample. Calcium is excluded from the 
reaction by complexion with ethylene diamine tetraacetic acid (EDTA). 
3.6.7. Creatinine 
 Method- Colorimetric, end point method. 
 Principle- Picrate forms red colored complex with creatinine in alkaline 
medium. Intensity of the color is directly proportional to the concentration of 
creatinine.  
3.6.8. Sodium and Potassium 
     Method- ISE (Ion Selective Electrode) 
Principle- Measurement of electro-motive force (EMF) differences between 
sodium, potassium electrodes and a reference electrode with constant EMF. 
The EMF from each electrode is directly proportional to the respective ionic 
concentration.  
3.6.9. Bicarbonate 
 Method- Colorimetric, Enzymatic end point method. 
Principle- Based on measurement of total Co2 in serum sample. 
3.6.10. Urinary pH  
The urine pH is measured by a pH electrode. 
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3.6.11. Albumin and total protein 
 Method- Colorimetric, Chemical end point method 
Principle for albumin- Bromocresol green forms colored complex with albumin 
in acidic medium. Principle for total protein- Proteins forms a purple colored 
complex with cupric ions in alkaline medium Intensity of the color is directly 
proportional to the concentration of albumin/ total protein due to change of 
absorbance in photometric measurement. 
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OBSERVATIONS 
 
Four hundred and fifty urolithiasis patients from Tamilnadu were 
evaluated from April 2006 to January 2008. Out of them 39 matched pairs 
were selected from urology clinic and lithotripsy unit, using preset inclusion 
and exclusion criteria. These clinics examine 700 stone patients annually 
from all parts of India. The mean age of the cases and controls was 38.5 
years (Range 18-69 years) and 37.6 years (range 18-78 years) 
respectively.  Out of 39 matched pairs, 25 (64%) were male and 14 (36%) 
were females. Thirty-one cases (79%) were first time stone formers and 
the rest had recurrence (Figure-1).  
Stone formers
79%
21%
0% 20% 40% 60% 80% 100%
Fsf
Rsf
 
 Figure-1: Figure showing percent point of First time (Fsf) and Recurrent stone formers 
(Rsf). 
Of the eight recurrent stone formers, three had past history of recurrent 
calculuria.  
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4.1. Serum values 
 No significant difference was found between affected and unaffected 
siblings for serum calcium (p=0.18), phosphorus (p=0.10), uric acid 
(p=0.15), A-G ratio (p=0.51), potassium (p=0.51) and serum bicarbonate 
(p=0.26). Only serum sodium was found to be higher in unaffected siblings 
(p=0.01) (Table-1). 
Table-1: Average serum parameters (continuous variables) for Cases and 
Controls. 
Parameters Cases  
(Mean±SD) 
Controls 
(Mean±SD) 
p† value 
 
Calcium 9.23±0.43 9.10±0.39 0.18 
Phosphorus 3.93±0.68 4.17±0.63 0.10 
Uric acid 5.0±1.05 4.8±1.13 0.15 
A:G ratio 1.34±0.23 1.37±0.25 0.51 
Sodium 138.7±2.4 140.2±2.4 0.01 
Potassium 4.24±0.42 4.19±0.32 0.51 
Bicarbonate 26.0±2.30 26.5±1.77 0.26 
                †t-test 
Blood was withdrawn for all the above mentioned parameters as an 
ambulatory setting.  
4.2. Urine phenotyping 
 All of the cases and controls were found normal for ambulatory 24 
hour urinary magnesium and urinary pH. All the cases were normal for 
urinary uric acid level but one of the controls was found to be 
hyperuricosuric. 
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4.2.1. Ambulatory urinary volume 
 The average urinary volume in stone formers and matched controls 
was 2457 and 2155 ml respectively.  Urinary volume of 1500 ml or less 
was considered abnormally low in cases and controls. In this study, there 
were 12 discordant pairs (case and control had different urinary volume). 
There were 9 (75%) pairs where the control had low urinary volume but the 
case had not, and 3 (25%) pairs where the cases had low urinary volume 
but the control was normal for urinary volume (Table-2).  
Table-2: Low and normal urinary volume among matched pairs.  
 
 CONTROLS TOTAL p†-value 
Low volume Normal volume 
C 
A 
S 
E 
S 
Low 
volume 
n=08 
 
05 
 
03 
 
     08 
 
 
 
    0.15 Normal 
volume 
n=31 
 
09 
 
22 
 
     31 
 
TOTAL 
           
         14 
            
           25 
     
     39 
 
        † McNemar test 
The two-tailed P value was 0.15. This difference is not statistically 
significant. The odds ratio is 0.33 with a 95% confidence interval extending 
from 0.058 to 1.336. 
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4.2.2. Ambulatory 24 hour urinary calcium 
Out of Thirty-nine matched pairs, 8 cases were hypercalciuric and 
thirty-one cases were normal for urinary calcium. Of these eight cases, 5 of 
their matched controls were also found to be hypercalciuric. Three controls 
had hypercalciuria though their cases were normal for urinary calcium. In 
this analytical study there were 6 discordant pairs (case and control had 
different urinary calcium). Three (50%) pairs where the controls had 
hypercalciuria, the cases were normal for urinary calcium and 3 (50%) 
pairs where the cases had high urinary calcium the controls were 
normocalciuric (Table-3).  
Table-3: Hypercalciuria and normal urinary calcium among matched pairs. 
 
 CONTROLS TOTAL p†-value 
Hypercalciuria Normal urinary 
calcium 
C 
A 
S 
E 
S 
Hypercalciuria 
n=08 
 
05 
 
 
03 
 
  
    08 
      
 
 
 
   0.68 Normal 
urinary 
calcium n=31 
 
03 
 
28 
 
 
    31   
 
TOTAL 
           
           08 
            
            31 
     
    39 
                
               † McNemar test 
 
The two-tailed P value was 0.68; this difference is not statistically 
significant.  
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4.2.3. Ambulatory 24 hour urinary oxalate 
Five cases had hyperoxaluria and high urinary oxalate was also 
seen in 2 of their matched controls. Three controls had hyperoxaluria 
though their cases were normal for urinary oxalate (Table-4).  
Table-4: Hyperoxaluria and normal urinary oxalate among matched pairs. 
 
 CONTROLS TOTAL p†-value 
Hyperoxaluria Normal urinary 
oxalate 
C 
A 
S 
E 
S 
Hyperoxaluria 
n=05 
 
02 
 
 
03 
 
  
    05 
      
 
 
 
   0.68 Normal 
urinary 
oxalate n=34 
 
03 
 
31 
 
 
    34   
 
TOTAL 
           
           05 
            
            34 
     
    39 
 
                   † McNemar test 
 
Similar to the urinary calcium, there were 6 discordant pairs (cases and 
controls had different urinary oxalate), 3 (50%) pairs where the controls 
had hyperoxaluria but the cases were normal and 3 (50%) pairs where the 
cases were hyperoxaluric but the controls were normal for urinary oxalate. 
The two-tailed P value was 0.68 which was not statistically significant.  
4.2.4. Ambulatory 24 hour urinary citrate 
 Out of Thirty-nine matched pairs, 9 cases were hypocitraturic and 
thirty cases were normal for urinary citrate. Of these 9 cases, 4 of their 
matched controls were also found to have hypocitraturia. Two controls had 
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hypocitraturia though their cases were normal for urinary citrate. In this 
study there were 7 discordant pairs. There were 5 (71%) pairs where the 
cases were exposed to the risk factor (hypocitraturia) but the controls were 
normal for urinary citrate and 2 (29%) pairs where the controls had low 
urinary citrate but cases were normal (Table-5).  
Table-5: Hypocitraturia and normal urinary citrate among matched pairs 
 
 
 CONTROLS TOTAL p†-value 
Hypocitraturia Normal urinary 
citrate 
C 
A 
S 
E 
S 
Hypocitraturia 
n=09 
 
04 
 
05 
 
   09 
  
 
 
 0.45 Normal urinary citrate 
n=30 
 
02 
 
28 
 
   30 
 
TOTAL 
 
           06 
 
            33 
 
   39 
 
                † McNemar test 
The two-tailed P value was not statistically significant (p=0.45). The odds 
ratio was 2.5 with a 95% confidence interval  
extending from 0.40 to 26.2. 
 
 
 
 
 
 
 45
DISCUSSION 
 Stone disease is common with a lifetime risk of stone formation exceeding 
12% in men and 6% in women.30,23 The prevalence appears to have increased 
for men and women in the last quarter of the twentieth century.23                
Curhan GC et.al29 corroborated this apparent increase may be due to an actual 
increase in stone disease or it may stem from increased detection of 
asymptomatic stones with the greater use and higher sensitivity of imaging 
studies. Lieske JC et.al.128 found that the incidence rates since 1990 is falling in 
men and have reached a plateau in women. Reports also suggest that the likely 
hood of forming another stone after the first episode is about 30-40% in 5 
years.3,6  
 Curhan GC et.al14 found that the risk of becoming a stone former is more 
than 2.5 times in individuals with a family history of stone disease. A family 
history increases the risk of kidney stone passage independent of dietary risk 
factors.31 This higher risk is likely due to a combination of genetic predisposition 
as well as similar environmental exposures.29 Identification and characterization 
of families of recurrent stone formers is essential for the identification of unique 
genetic, environmental and metabolic factors that predispose individuals to 
recurrent calcium oxalate stone formation. While a number of genetic factors 
have been clearly associated with rare forms of nephrolithiasis, the information 
regarding genetic contribution for the common forms of stone disease is still 
limited. 
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 In 1975, Pak et.al.5 developed a simple protocol in 1978 to identify the 
underlying cause of Urolithiasis. This protocol disclosed a physiologic 
abnormality in nearly 90% of cases and provided a definitive diagnosis in 95% of 
patients.3,4 This ambulatory instrument made diagnostic separation and 
classification of urolithiasis more accessible and more practical for all patients. 
The ability to distinguish among the underlying physiologic disturbances allowed 
the application of a selective treatment programme on the basis of correction of 
the specific physiologic derangement. 
 With multifactorial etiology, a urinary risk factor which would reliably 
predict the likelihood of stone recurrence in the patient with upper urinary tract 
stones would help the clinician to select appropriate preventative therapy. 
Observational studies have shown urinary parameters as a risk factor and a 
beneficial effect of dietary modification in them. Studies failed to show that there 
is a difference in dietary intake between stone formers and controls from the 
same geographic area.129 
 In our study, no statistical difference was found between cases and their 
matched controls for 24-hour urinary calcium, oxalate and citrate and urinary 
volume. Literature also shows that individual urinary risk factors do not reliably 
predict the subsequent course of stone disease.130,131 Thus none of the indices 
developed to date combines easy applicability in usual clinical settings with 
sufficient predictive power to be useful to the clinician in making treatment 
decisions. 
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 The pathogenesis of stones was explained principally on the basis of 
formation of crystals which result from supersaturation of urine with stone forming 
salts. If there are no crystals—there are no stones. The hypothesis had the 
attraction of simplicity. It has been said ‘‘given two or three equally predictive 
theories, choose the simpler theory’’ (Occam's razor ).132 Furthermore, it is easy 
to measure the supersaturation of urine and make attempts to predict the risk of 
stone formation and formulate a treatment plan, be it dietary or medicinal. This 
theory, however, has not completely explained all the facets of stone disease and 
other theories have emerged in the past decade or so. 
 Whilst the supersaturation theory is simple and attractive, in the more 
common type of stone namely calcium oxalate, the differences in terms of 
supersaturation between stone formers and those that do not, was not found to 
be significant.133 Perhaps heterogeneous nucleation in urine which is in 
metastable limit, renal tubular damage with cellular dysfunction and 
macromolecules are more important than urine in a supersaturated state.134  For 
the same reason some patients continue to form stones even after successful 
treatment of urinary abnormalities.134 
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SUMMARY 
 
 Despite intensive studies in the last decades many aspects of 
nephrolithiasis still remain to be elucidated. Supersaturation with respect to 
lithogenic substances explains stones composed of cystine, uric acid, struvite, 
and calcium stones secondary to systemic diseases. In this subset there is a 
clear separation between patients and controls, and stone activity is well related 
to alterations in the physicochemistry of the urine environment. The 
understanding of the mechanisms of idiopathic calcium nephrolithiasis, on the 
other hand is controversial, because we are still unable to establish clear-cut 
cause-effect relationship between metabolic and physicochemical abnormalities 
and stone formation. Recent studies have been centered on the kidney; not only 
as the end organ of urometabolic derangements due to systemic or 
environmental factors, but also as a complex laboratory where some events 
conducive to (Renal tubular damage and cellular dysfunction)121 and others 
protect (macromolecules)122 from lithogenesis. Many of these phenomena occur 
in the proximal tubule.  
 Molecular biology has explained some types of hypercalciuria, which are 
due to genetic mutations altering tubular function and similar results are expected 
for hypocitraturia and hyperoxaluria. The latter is conducive to stone formation 
through several mechanisms including supersaturation, oxidative stress on 
tubular cells, and interference with some natural inhibitors. The long list of 
inhibitors includes ionic and macromolecular moieties, some being produced 
within the nephron in response to lithogenic insults and some affecting not only 
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crystallization but also crystal cell adherence. Crystal trapping is believed to 
anticipate a renal stone. However, much has still to be clarified on their actual 
role in calcium nephrolithiasis, by what mechanisms they act, if patients and 
controls differ in the excretion and structure of some inhibitors, and whether 
differences are genetically determined.  
 Debate such as this has long been overdue. It is entirely possible that 
none of the above is the key to stone formation but is the final stage of a process 
that was initiated by something else which may be the real key.  
 
CONCLUSION 
 We conducted this study with a research question; do different people 
living in the same environment consuming the same diet have different urinary 
profile? We found urinary profile in family members of a stone patient is similar. It 
appears some other factor must have been present in stone formers and will 
require further research. At present the usefulness of uro-metabolic evaluation 
and subsequent therapy advice appears to have little value. 
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LIMITATIONS 
 
 
 
1. Diet was retrospectively assessed, so their may be chances of recall bias. 
2. Sample size was small. 
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Annexure-i 
 
      Consent Form       
 
Urinary Biochemical Profile in Urolithiasis: A case control study from Tamil 
Nadu 
 
Information to the patient: 
Urinary stone disease recurs at 10% at 1 year 50% at 5 years and 70% at 10 
years. We do not know why it recurs in most people. We plan to do this research 
on you and one of your relatives. The relative should be of the same sex, taking 
the same diet and living together for the last five years. The purpose of the study 
is to identify if there is any differences in biochemical profile between you and 
your family member.  In this study, there is no risk for you or your family member. 
Infact it gives an opportunity to screen your family member for urinary stone 
disease. If stone disease is diagnosed in your relative, he/she will need treatment 
at his/her own cost. 
 
 
 
 
 
Signature of Patient                   Signature of Relative (control)  
Name……………….                                      Name…………………………. 
H. No………………..                                 H.No…………………………...                          
     Relation……………………….. 
 
 
 
Signature of principal Investigator          
Name: Dr Gaurav Gupta                               Date……………………………. 
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Annexure-ii 
    History Performa for Case and Control 
 
Name_____________________________Age_________Sex______________ 
 
No of family members in the family_______Male________Female___________ 
 
How many members living with the patient for >5yrs ______________________ 
 
Patient is First stone former (Fsf.)_______ Recurrent stone former (Rsf.)_______ 
 
Renal / Ureteric stone / Both_________________________________________ 
 
Past Intervention for stone___________________________________________ 
 
Dates: Ist stone______________________IInd stone_______________________ 
 
Residual after intervention___________________________________________ 
 
Medical therapy for Urolithiasis_______________________________________ 
 
Past history of Urolithiasis/ Calculuria for controls_________________________ 
 
Radiology: suggestive of structural abnormality___________________________ 
 
Medical history of  
 
1. Gout____________2. Intestinal disease (MAS) ________________ 
 
3.UTI’s____________4. Fracture________ 5. Diabetes____________ 
 
6. Bone disease________ 7. Resection of small bowel_____________ 
 
8. Medications (Steroids; Calcium supplements; vit D and C; 
Frusemide; triemterine; Indinavir; Sulfonamides;antacids)__________ 
________________________________________________________ 
 
9. RTA________________10 Hyperperathyroidism_______________ 
 
11. Sarcoidosis_________12. Disseminated malignancy___________ 
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Annexure-iii 
 
WORK SHEET 
                       
Name (Pt)__________________                   Name (C)___________________ 
H.No______________________                    H.No.______________________ 
Address____________________         Address_____________________  
Age__________  Sex_________                   Age____________ Sex_________ 
 
Serum 
Ca _____________________         Ca ____________________ 
Po4_____________________                             Po4 _____________________________ 
UA_____________________                        UA____________________ 
Na _____________________    Na_____________________ 
K ______________________    K______________________ 
HCo3___________________    HCo3 __________________ 
AG ratio_________________    AG ratio ________________ 
24 hr urinary 
pH______________________                            pH_____________________ 
Ca______________________              Ca_____________________ 
Oxalate__________________    Oxalate_________________ 
Uric Acid_________________              Uric Acid________________ 
Citrate ___________________    Citrate__________________ 
Magnesium_______________       Magnesium______________ 
Creatinine________________                        Creatinine_______________ 
 
         X-Ray KUB______________ 
Site of stone___________________     USG-KUB _______________ 
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Name H.no ControAge Sex S.Ca S.Po4 S.UA S.Na S.K S.HCo3
Soma 953300C Co 25 M 9.5 3.7 4.8 137 3.7 27
Sayed Ibrah010167C Co 33 M 9.6 3.5 5.2 139 4 26
Sivagami 986159C Co 47 F 8.6 4.2 4.5 138 3.9 25
Anand 251414C Co 34 M 9.4 3.3 5.3 144 4.2 28
Arun kumar 956897C Co 18 M 9.4 5 5.1 139 4.1 28
Bharathi 964004C Co 23 M 9.1 5.5 5.5 137 4 28
Arivazhagan971618C Co 42 M 9 3.9 3.9 138 4.1 25
Parijathan 973101C Co 53 M 8.8 4.5 6.2 137 3.9 28
Archana 479830C Co 20 F 9.3 4.7 2.6 143 4.3 26
Sujatha 492085B Co 32 F 8.6 3.7 2.5 137 4.1 19
Kamalamma514064C Co 73 F 9.3 4.5 4.9 141 4.3 28
Sumathi 017837C Co 38 F 9 4.9 3.7 141 4 25
Nirmala 045724D Co 56 F 8.7 4 5.5 143 4.6 28
Shyamala 538503B Co 32 F 9.2 3.2 4.6 145 3.5 25
Balan 042850D Co 38 M 8.8 4.3 7.1 144 5 29
Mangalaraj 058097C Co 48 M 8.6 4.5 6.4 143 4.1 26
Uma 056477D Co 25 F 8.6 3.8 3.2 140 4.1 27
Sumithra 983031C Co 28 F 9.7 4 4 139 4.7 25
Muniappan 064150D Co 22 M 8.6 4.2 4.5 138 3.9 25
Anand V 251414C Co 34 M 9.4 3.3 5.3 144 4.2 28
Shakeela 143701D Co 20 F 9.2 4.6 2.7 140 4.1 26
Andrews 413654(OCo 60 M 9.2 3.8 5.9 144 4.1 26
Settu 146964D Co 35 M 9.6 3.6 5.6 141 5.2 27
Elumalai 111053D Co 18 M 9.6 5.8 5.7 140 4.1 28
Gajapathy 088354D Co 23 M 9.4 4.3 4.2 140 4 26
Sarvanan 095210D Co 36 M 8.9 5.1 5.7 136 4.2 27
Caroline 233298A Co 40 F 9.1 3.5 2.5 140 4.1 26
Vasugi 418010C Co 43 F 9 4.1 5.6 138 4.3 25
Ananthi 065941D Co 19 F 8.5 3.5 4.2 139 4 26
Senthil K 357000C Co 25 M 9.4 3.5 5.3 139 4.1 27
Md Iqbal 306942B Co 48 M 9.8 4.4 4 137 4.3 26
Ravishanka 130693D Co 35 M 8.9 4.4 6 138 4.1 29
Kanthamma123161D Co 55 F 9.2 4.2 2.8 144 4.1 28
Ashok K 952152C Co 22 M 10 3.7 5.6 142 4.9 28
Md.Ali 122860D Co 54 M 8.8 2.9 5.8 140 4.1 25
Damodhara 111225D Co 67 M 8.9 4.7 5 141 4 28
Gopiraj M 119084D Co 23 M 8.9 3.1 4.4 142 3.8 27
Rangaraj V 619250A Co 47 M 9.1 4.3 5.5 142 4 27
Subramaniu111054D Co 78 M 8.5 4 4.4 140 4.7 26
S.ca:serum calcium,SPo4:serum phosphorus,S.UA.:serum uric acid,S.Na.serum sodium,S.K.:serum potassium,Hco3:serum 
bicarbonate,AGratio:albumin Globulin ration,UpH: urinary pH.
AGRatnpH U U24h U.Ca U,Ox. U.UA U.Cit U.Mg U.Cr
1.48 6 3550 316 40 420 828 142 984
1.43 6 1425 139 20 530 2186 107 1500
1.1 5.5 950 120 14 380 195 44 608
1.4 5.5 1680 62 23 538 593 68 593
1.4 5 4630 264 50 407 1314 133 1400
1.56 5 1100 147 20 550 573 4 1200
1.35 6 5500 400 15 512 651 161 1279
1.17 5.5 2770 197 20 332 487 84 1290
1.48 6 980 131 26 461 1130 93 1000
1 6 670 129 18 359 1107 100 590
1.22 5 1030 147 34 216 698 128 855
1.19 6 4120 52 15 288 255 98 577
1.25 7 3000 123 19 570 503 90 840
1.15 1000 178 21 400 450 46 903
1.35 5.5 600 86 38.3 660 574 92 1100
1.28 5 3190 112 69 514 275 48 1500
1.16 5 1180 55 23 177 967 52 531
1.29 5 900 170 12 441 640 6 720
1.1 5.5 1800 120 14 380 195 4.5 608
5.5 1680 62 23 538 593 68 1400
1.36 7 1170 64 20 234 167 25 386
1.2 8 1980 275 9.4 372 752 24 1100
1.63 7 3335 119 11 391 1243 141 686
1.63 7 1285 40 17 513 930 201 731
2.21 7 1685 175 11 349 301 53 996
1.46 6 1260 53 29 403 669 55 900
1.28 6 1000 102 25 304 590 10 697
6 1346 255 31 468 1005 74 611
0.82 6 1940 175 12 330 208 76 543
1.85 7 1160 101 45 360 597 93 1000
1.36 5 2790 112 12 290 377 56 474
1.48 5 3360 119 35 560 1723 126 1300
1.17 6 1900 112 45 500 380 9 900
1.59 6 2210 31 5.6 400 173 81 624
1.28 5 4755 412 15 747 84 144 1400
1.53 7 2860 179 18 361 434 136 706
1.46 7 2120 240 22 400 892 107 1100
1.64 5.5 2600 121 27 494 671 73 1200
1.09 6 1220 52 14 309 386 58 514
S.ca:serum calcium,SPo4:serum phosphorus,S.UA.:serum uric acid,S.Na.serum sodium,S.K.:serum potassium,Hco3:serum 
bicarbonate,AGratio:albumin Globulin ration,UpH: urinary pH.
